Rigel Pharmaceuticals
South San Francisco
About Rigel Pharmaceuticals
Rigel Pharmaceuticals, Inc. (Rigel), is a clinical-stage drug development company. The Company discovers and develops small-molecule drugs for the treatment of inflammatory/autoimmune diseases, as well as for certain cancers and metabolic diseases. Its research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. The Company has product development programs in inflammatory/autoimmune diseases, such as rheumatoid arthritis, thrombocytopenia and asthma, as well as in cancer.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 101 – 250
- Estimated revenue: $100K – $500K
- Total funding: $192.5M
- Funding stage: IPO
- Last round: Grant (Jan 2021)
- Ticker: nasdaq:RIGL
- Website: rigel.com
- Phone: 650-624-1100
Industries & Categories
Biotechnology, Health Care, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/rigel-pharmaceuticals-112028 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.